MacroGenics Doses First Patient In Phase 1 Study Of MGC030, Antibody-Drug Conjugate Directed Against Undisclosed Target, In Patients With Advanced Solid Tumors

Loading news article.

MacroGenics Doses First Patient In Phase 1 Study Of MGC030, Antibody-Drug Conjugate Directed Against Undisclosed Target, In Patients With Advanced Solid Tumors | WAPE

MacroGenics Doses First Patient In Phase 1 Study Of MGC030, Antibody-Drug Conjugate Directed Against Undisclosed Target, In Patients With Advanced Solid Tumors

Article summary

Related companies

Analyzed by WAPE AI.

Comments —